TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01561755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 2gr/kg over 2 days of saline
Study: NCT02680574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Study: NCT02381132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MNK155
Study: NCT01402518

Intervention type: PROCEDURE
Intervention: Per-oral enodscopic myotomy
Study: NCT02286869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three different mechanical ventilation modes
Description: patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three different mechanical ventilation modes
Description: patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three different mechanical ventilation modes
Description: patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
Study: NCT03726593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate and Pyronaridine
Description: Standard weight based dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil and Artesunate Pyronaridine
Description: Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil and Artesunate Mefloquine
Description: Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
Study: NCT03592407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study: NCT04180943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interscalene nerve block
Description: intra and post-operative analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interscalene nerve block
Description: intra and post-operative analgesia
Study: NCT03645239

Intervention type: PROCEDURE
Intervention: Mechanical Temporal Summation assessment
Description: A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
Study: NCT01794299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATIR
Description: Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
Study: NCT03313726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
Study: NCT03949257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colonic transendoscopic enteral tubing
Description: Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
Study: NCT04580745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MORF-057
Description: SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.
Study: NCT03368716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavioral Treatment (ABBT)
Description: ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
Study: NCT03500406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX
Description: Penile traction therapy in the straight position
Study: NCT03645239

Intervention type: PROCEDURE
Intervention: Mechanical Temporal Summation assessment
Description: A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.

Intervention type: OTHER
Intervention: Preoperative pain assessment
Description: Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?).

Intervention type: OTHER
Intervention: Preoperative pain assessment
Description: Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?).
Study: NCT03426358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSM assessed by Elastographic Techniques
Description: Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
Study: NCT02880514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROPEL Mini Sinus Implant
Description: Sinus implant with 370 mcg of mometasone furoate released over 30 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sinus Dilation Alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Sinus Dilation Alone
Study: NCT03500406

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No treatment
Study: NCT03645239

Intervention type: OTHER
Intervention: Preoperative pain assessment
Description: Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?).

Intervention type: OTHER
Intervention: Preoperative pain assessment
Description: Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?).

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
Study: NCT02700789

Intervention type: PROCEDURE
Intervention: Transvaginal ultrasound scan
Description: The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
Study: NCT03645239

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.

Intervention type: OTHER
Intervention: Headspace
Description: The mindfulness exercise mobile application, Headspace, will be downloaded into the patients' mobile devices. Patients will be asked to experience a mindfulness exercise for 10-30 minutes before delivery. HADS and pain score will be asked after the intervention.
Study: NCT01442324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
Study: NCT00721227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction Gastroplasty
Description: * Subjects will undergo reduction gastroplasty by gastric plication~* Subjects are followed for 12 months to evaluate outcomes and potential complications.
Study: NCT01325090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: A syringe of 1 ml contain 25 Allergan units.
Study: NCT04352686

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo to assess differences in esophageal sensitivity
Study: NCT02113644

Intervention type: OTHER
Intervention: Lifestyle intervention
Study: NCT03912597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Video Control
Description: The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
Study: NCT01902225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istodax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Study: NCT01774708

Intervention type: DEVICE
Intervention: Pressure sensitive pad
Description: The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient.
Study: NCT02390024

Intervention type: DEVICE
Intervention: Invasive Mechanical Ventilation
Description: Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840
Study: NCT04063150

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV (0.1 mL) ID
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV (0.1 mL) ID
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV (0.1mL) IM
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV (0.1mL) IM
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV (0.2mL) IM
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
Study: NCT02122692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054 30 mg
Description: Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054 30 mg + itraconazole 200 mg
Description: Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules, once daily, Day 12-13, orally
Study: NCT00134004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03704415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended endoscopic sinus surgery
Description: ESS of all sinuses
Study: NCT00542139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivocaine
Description: Intraarticular injection of 10ml of Bupivocaine
Study: NCT04041258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pseudoarthrosis of clavicle
Description: Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
Study: NCT03155776

Intervention type: DIAGNOSTIC_TEST
Intervention: GUS
Description: gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
Study: NCT01592110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone-SABER
Description: 25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
Study: NCT03704415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limited endoscopic sinus surgery
Description: Partial ethmoidectomy